Back to Search
NORRISA HAYNES, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1346683513IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
MD474222(PA)
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
56922(CT)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Class of 2013
Research & Publications (20)
Follicular associated T cells and their B-cell helper qualities.
PMID 18201361·Tissue Antigens·2008
6-review
Addressing students' social and emotional needs: the role of mental health teams in schools.
PMID 12809382·J Health Soc Policy·2002
6-review
Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
PMID 12421958·J Immunol·2002
7-preclinical
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
PMID 12384413·Blood·2002
4-observational
Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
PMID 11123291·J Immunol·2001
4-observational
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
PMID 19242371·J Immunother·2009
8-other
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors.
PMID 19029380·J Exp Med·2008
7-preclinical
Neuroprotective effects of caspase-3 inhibition on functional recovery and tissue sparing after acute spinal cord injury.
PMID 18827691·Spine (Phila Pa 1976)·2008
4-observational
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
PMID 18685088·Proc Natl Acad Sci U S A·2008
7-preclinical
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.
PMID 18667695·Proc Natl Acad Sci U S A·2008
7-preclinical
Immunogenic anti-cancer chemotherapy as an emerging concept.
PMID 18573339·Curr Opin Immunol·2008
6-review
Interleukin 21 enhances antibody-mediated tumor rejection.
PMID 18413772·Cancer Res·2008
7-preclinical
Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
PMID 18369322·Gene Ther·2008
4-observational
Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation.
PMID 17911595·J Immunol·2007
7-preclinical
Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism.
PMID 17101733·J Exp Med·2006
4-observational
Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice.
PMID 16856138·J Comp Neurol·2006
7-preclinical
Providers and consumers support the Western Australian Audit of Surgical Mortality.
PMID 16768765·ANZ J Surg·2006
8-other
The Western Australian Audit of Surgical Mortality: advancing surgical accountability.
PMID 16296962·Med J Aust·2005
8-other
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.
PMID 16030195·Blood·2005
7-preclinical
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
PMID 15265951·J Immunol·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 789 HOWARD AVE
NEW HAVEN, CT 06519 - Phone
- (203) 737-1947
Quick Facts
- NPI
- 1346683513
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 13
- Publications
- 20
Are you this provider?
Claim Your Profile